• OPEN AN ACCOUNT
Indian Indices
Nifty
25,960.55 -225.90
(-0.86%)
Sensex
85,102.69 -609.68
( -0.71%)
Bank Nifty
59,238.55 -538.65
( -0.90%)
Nifty IT
38,590.70 -112.95
( -0.29%)
Global Indices
Nasdaq
47,981.01 109.07
(0.23%)
Dow Jones
6,892.33 14.21
(0.21%)
Hang Seng
50,472.24 -19.63
(-0.04%)
Nikkei 225
9,640.58 -26.43
(-0.27%)
Forex
USD-INR
89.99 -0.14
(-0.16%)
EUR-INR
104.92 -0.11
(-0.11%)
GBP-INR
120.05 0.29
(0.24%)
JPY-INR
0.58 0.00
(0.11%)

EQUITY - MARKET SCREENER

Genpharmasec Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
531592
INE861N01036
1.2440748
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
23
76.41
EPS(TTM)
Face Value()
Div & Yield %
0.06
1
0
 

Lupin enters into exclusive licensing agreement with Valorum Biologics
Dec 04,2025
Lupin as entered into an Exclusive Licensing Agreement with Valorum Biologics (Valorum), a biosimilar specialist in the U.S., for its biosimilar Armlupeg™ (pegfilgrastim-unne).

Under the terms of the agreement, Valorum will advance the commercialization and distribution of Armlupeg™ (pegfilgrastim-unne) in the United States. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront license fee and a royalty payment on net sales.

Pegfilgrastim-unne is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.